Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Millennium, Celgene present MM data

MLNM and CELG each reported multiple myeloma (MM) data from multiple Phase III trials at the American Society of Hematology meeting in Atlanta on Monday.

MLNM reported data from three Phase III trials of Velcade bortezomib. In the VISTA trial in 682 previously untreated MM patients ineligible for stem cell transplantation, Velcade plus melphalan and prednisone led to a 35% complete

Read the full 613 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE